• 1
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
  • 2
    Cannistra SA. Cancer of the ovary. N Engl J Med. 1993; 329: 1550-1559.
  • 3
    Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009; 22: 119-125.
  • 4
    Campas C. Drug repositioning summit: finding new routes to success. Drug News Perspect. 2009; 22: 126-128.
  • 5
    Richardson P. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Semin Hematol. 2005; 42: S9-S15.
  • 6
    Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011; 15: 166-178.
  • 7
    Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011; 13: 483-491.
  • 8
    Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27: 3576-3586.
  • 9
    Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila). 2008; 1: 369-375.
  • 10
    Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009; 69: 6539-6545.
  • 11
    Isakovic A, Harhaji L, Stevanovic D, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007; 64: 1290-1302.
  • 12
    Romero IL, McCormick A, McEwen KA, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012; 119: 61-67.
  • 13
    Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305.
  • 14
    Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29: 254-258.
  • 15
    Bakhru A, Buckanovich RJ, Griggs JJ. The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol. 2011; 121: 106-111.
  • 16
    Outwater EK, Wagner BJ, Mannion C, McLarney JK, Kim B. Sex cord-stromal and steroid cell tumors of the ovary. Radiographics. 1998; 18: 1523-1546.
  • 17
    Efstathiou E, Dimopoulos MA, Bozas G, et al. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res. 2007; 27: 611-617.
  • 18
    Aletti GD, Eisenhauer EL, Santillan A, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011; 120: 23-28.
  • 19
    Apovian CM. Management of diabetes across the course of disease: minimizing obesity-associated complications. Diabetes Metab Syndr Obes. 2011; 4: 353-369.
  • 20
    McTiernan A, Irwin M, Vongruenigen V. Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol. 2010; 28: 4074-4080.
  • 21
    Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27: 3297-3302.
  • 22
    Bower WF, Jin L, Underwood MJ, et al. Overt diabetes mellitus adversely affects surgical outcomes of noncardiovascular patients. Surgery. 2010; 147: 670-675.